Evolving Epidemiology and the Expanding Imperative in Drug Use–Associated Endocarditis

Clicks: 9
ID: 337408
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #602 of 635 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 635 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Nearly a decade after the opioid epidemic was declared a public health emergency, the rise of synthetic opioids such as fentanyl has led to unprecedented increases not only in overdose deaths but also in injection-related infections, including drug use–associated infective endocarditis (DUA-IE) [1, 2]. Drug use–associated infective endocarditis tends to affect younger individuals with fewer comorbid conditions, with lower in-hospital and short-term mortality compared with non–DUA-IE [3]. However, given the complex psychosocial and environmental factors, long-term outcomes remain poor, with high recurrence and readmission rates [3]. Given the severity and complexity of management of DUA-IE, substantial attention has focused on the inadequacy of addiction-related care during hospitalization, prompting the infectious diseases community to better integrate addiction care and harm reduction into routine practice [4, 5]. These efforts have contributed to meaningful progress, including integrated infectious diseases and addiction training programs, expanded access to medications for opioid use disorder (MOUD) through legislative and regulatory changes, and growing recognition of the importance of harm-reduction services. However, these advances occurred alongside major health system disruptions during the coronavirus disease 2019 (COVID-19) pandemic, which led to worsened addiction-related outcomes, at least in its initial phases [6].
Reference Key
openalex_W7223955519 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Audrey Li, Shireesha Dhanireddy
Are you one of these authors? Claim your profile
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag608
URL
https://doi.org/10.1093/cid/ciag608
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.